<DOC>
	<DOC>NCT01185821</DOC>
	<brief_summary>This blinded extension study is designed to offer patients with relapsing-remitting MS having completed the core study CBAF312A2201 access to BAF312 until they can enter an open label study. It will provide data on long-term safety, tolerability and efficacy of BAF312 in this patient population.</brief_summary>
	<brief_title>Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Autoimmune Diseases of the Nervous System</mesh_term>
	<criteria>Patients completed the core study BAF312A2201 Written informed consent provided before any assessment of the extension study Female patients at risk of becoming pregnant must have a negative pregnancy test and use simultaneously two forms of effective contraception Newly diagnosed systemic disease other than MS (which may require immunosuppressive treatment) Malignancies, diabetes, significant cardiovascular and pulmonary diseases and conditions Active infections Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>56 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing remitting Multiple Sclerosis</keyword>
	<keyword>Demyelinating Autoimmune Diseases</keyword>
</DOC>